Drug Profile

ANB 032

Alternative Names: ANB-032; Anti-BTLA modulator antibody - AnaptysBio

Latest Information Update: 01 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AnaptysBio
Class Anti-inflammatories; Antibodies; Skin disorder therapies
Mechanism of Action BTLA protein stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Atopic dermatitis

Most Recent Events

07 Jan 2025 AnaptysBio terminates a phase IIb trial for Atopic dermatitis in New Zealand, Georgia, Canada, Czech Republic, Poland, Australia and the US (SC) (NCT05935085)
31 Dec 2024 AnaptysBio has patent protection for antibody sequence of ANB 032 and its variants, methods of use and related matters in multiple countries
31 Dec 2024 AnaptysBio has patents pending for ANB 032 in multiple countries

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com